Aktis Oncology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew Roden
- Full Time Employees
- 79
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 17 Drydock Avenue Boston MA United States of America 02210
- IPO Date
- Jan 9, 2026
- CIK
- 0002035832
- Website
- aktisoncology.com
- Similar Companies
- Business
- Akoustis Technologies, Inc. designs, develops, manufactures, and sells radio frequency (RF) filter products primarily using proprietary bulk acoustic wave (BAW) technology with single-crystal piezoelectric materials. Its core product offerings include high-performance RF filters and amplifiers for mobile wireless devices such as smartphones and tablets; cellular infrastructure equipment; Wi-Fi access points, including 5 GHz and 6 GHz bands; customer premise equipment; and military and defense applications. Additionally, through its subsidiaries, Akoustis provides complementary surface acoustic wave resonators, crystal resonators, oscillators, and ceramic products. The company also operates a Fabrication Services segment offering engineering review and backend packaging services, along with advanced semiconductor back-end supply chain services such as wafer thinning, polishing, and automated inspection. Akoustis operates globally, serving markets across the Americas, Asia, and Europe. It maintains a 125,000 square-foot ISO-9001:2015 certified wafer fabrication and packaging facility in Canandaigua, New York, which includes class 100 and class 1000 cleanroom environments designed for 150 mm wafer processing. Founded in 2013 and headquartered in Huntersville, North Carolina, Akoustis aims to address performance challenges in RF front-end filtering by delivering ultra-wideband, high-frequency, and high-power solutions to meet the demands of expanding 5G, Wi-Fi, automotive, industrial, and defense sectors. In the last two years, Akoustis has undergone significant strategic expansions including the acquisition of RF Mi and GDSI, which broadened its product portfolio into surface acoustic wave resonators and advanced back-end semiconductor processing services. Notably, the company launched its XP3F technology targeting frequencies from 8 to 20 GHz and beyond to reshape the RF filter market. In 2024, Akoustis announced leadership changes with the appointment of Kamran Cheema as CEO. Concurrently, the company filed for Chapter 11 bankruptcy protection in December 2024 to facilitate reorganization and strategic sale efforts amid legal and financial challenges. It also pursued a reverse stock split and direct stock offering to manage Nasdaq listing compliance and raise capital. Throughout this period, Akoustis continued commercial volume shipments of its XBAW filters for 5G and Wi-Fi markets, securing major orders including a $13 million contract for Wi-Fi access point filters, reinforcing its position in the wireless communications industry.
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology to Present at the BofA Securities Health Care Conference
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
Brokerages Set Aktis Oncology (NASDAQ:AKTS) PT at $32.00
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Aktis Oncology (NASDAQ:AKTS) Reaches New 52-Week Low – Should You Sell?
Aktis Oncology to Present at Upcoming March Investor Conferences
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
Market Today: Chips, energy and housing lead -- TSM, MU, NVO in focus
Market Today: TSMC beat, Goldman soars, Spotify hikes
Market Today: Verizon outage, Tesla FSD shift, banks in focus
A Fresh IPO That Long-Term Investors Shouldn't Ignore
First Look: Alphabet $4T, Nvidia China OK, Boeing Tops Airbus